Complement Therapeutics Unveils State-of-the-Art Laboratory at Stevenage Bioscience Catalyst
Munich, Germany – 13th June 2023 – Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced the opening of their laboratory at Stevenage Bioscience Catalyst (SBC).
The state-of-the-art laboratory facility marks a significant milestone for CTx as it expands its research and development capabilities. Equipped with cutting-edge technologies and equipment, the lab will serve as a hub for advancing the development of CTx’s pipeline assets.
“We are thrilled to announce the opening of our new lab at Stevenage Bioscience Catalyst,” said Dr Dennis Keefe, Chief Scientific Officer of Complement Therapeutics. “This facility will be instrumental in accelerating our research efforts and driving innovation in the field of complement-mediated diseases. With the support of our growing talented team and the collaborative environment fostered at SBC, we are well-positioned to make significant progress in developing novel therapeutics.”
Dr Sally Ann Forsyth OBE, CEO, Stevenage Bioscience Catalyst, said: “We are delighted that Complement Therapeutics has joined our world-class cluster of excellence which accelerates the translation of cutting-edge science to improve people’s health and the quality of their lives. We wish the team every success as they continue to build potentially transformative therapies.”
The strategic location of the lab within the Stevenage Campus provides CTx with access to a vibrant ecosystem of leading researchers and industry experts. This proximity to scientific expertise and the potential for collaborative partnerships will enhance CTx’s ability to translate scientific discoveries into groundbreaking treatments for diseases with high unmet clinical need.
About Complement Therapeutics GmbH:
Complement Therapeutics GmbH (CTx) is a German headquartered early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for GA, a leading cause of blindness. Additional programs will evaluate potential therapeutic opportunities in other complement-mediated conditions.
The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable the quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
The Company has subsidiaries in the UK (Complement Therapeutics Ltd) and in the USA (Complement Therapeutics Inc) as well as research laboratories in Stevenage, UK.
About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is a world-leading cluster of global significance and located at the centre of one of the largest groups of cell and gene therapy companies in Europe. It provides a supportive environment to help organisations grow by providing access to specialist equipment, mentoring and finance suited to their stage of development. Since its opening in 2012, occupier companies have secured £2.9bn in finance making the cluster one of the most attractive for investment in biotechnology in the UK.
For more information please visit: https://complementtx.com/
Dr Rafiq Hasan, CEO and Managing Director
Complement Therapeutics GmbH